RxDoctor Payments Data

Kobina Wilmot, MD

Cardiovascular Disease · Mooresville, NCNPI 1356667505

Payments from drug & device makers

$92,719in general payments, 2019–2025

Across 379 payments — averaging $244.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$39K
  • Lilly USA, LLC$21K
  • Bayer$14K
  • Novo Nordisk$10K
  • Novartis$2K
  • Amgen$1K
  • plus $5K from 28 others

What the payments were for

  • Consulting fees$11,31912%
  • Speaking & faculty fees$61,16666%
  • Travel & lodging$11,48812%
  • Food & beverage$8,7019%
  • Education$460%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$92,719 in reported general payments places this provider in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$151,332
Medicare patients
663
Services billed
2,166

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide220$281,992
Repatha SureclickEvolocumab287$191,087
JardianceEmpagliflozin193$168,969
EliquisApixaban177$158,864
EntrestoSacubitril/Valsartan123$130,585
FarxigaDapagliflozin Propanediol132$121,291
XareltoRivaroxaban110$87,301
MounjaroTirzepatide60$84,656
RybelsusSemaglutide44$52,480
WegovySemaglutide28$38,779
KerendiaFinerenone48$36,890
Praluent PenAlirocumab63$34,039
VascepaIcosapent Ethyl70$29,000
NexlizetBempedoic Acid/Ezetimibe42$18,614
Icosapent Ethyl27$10,701

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Wegovy$9,684$373,251292 claims
Boehringer IngelheimJardiance$38,920$168,969193 claims
PfizerEliquis$498$158,864177 claims
AstraZenecaFarxiga, Brilinta$203$131,137150 claims
NovartisEntresto$2,367$130,585123 claims
Johnson & JohnsonXarelto$948$87,301110 claims
Lilly USA, LLCMounjaro$21,488$84,65660 claims
BayerKerendia$14,297$36,89048 claims
Esperion Therapeutics, Inc.Nexlizet, Nexletol$105$29,04254 claims
AmgenCorlanor$1,141$9,40719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Mooresville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →